× ×ª×× × ×ª×¨×פ×
××רש×
| ק×××¦× ×¤×¨×ק×××××ת (ATC4)
|
L01FF
PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors
|
| ×ר××× ×¤×¢×× (ATC5)
|
Â
|
| צ×רת ×ת×
|
ת××-×ר××× - I.V
|
| צ×רת ××× ××
|
תר××× ×××× ×ª ת×××¡× ×××× ×¤××××, CONCENTRATE FOR SOLUTION FOR INFUSION
××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר××
|
| ×ת××××
|
Metastatic Merkel Cell CarcinomaBavencio is indicated for the treatment of adult patients with metastatic Merkel cell carcinoma (MCC).Locally Advanced or Metastatic Urothelial CarcinomaFirst-Line Maintenance Treatment of Urothelial CarcinomaBAVENCIO is indicated for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) that has not progressed with first-line platinum-containing chemotherapy.Previously-Treated Urothelial CarcinomaBAVENCIO is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) who:⢠Have disease progression during or following platinum-containing chemotherapy⢠Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy Advanced Renal Cell CarcinomaBAVENCIO in combination with axitinib is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC).
|
| × ×ª×× × ×ס×
|
ת×ר×× ××××× ×ס×
- 11/01/2018
|
×××××ת ×ס×
- תר××¤× ×××××ת ×ר×ש×× ×¢'× ×¨××¤× ××××× ×× ××××× ××רת
|
×ת×××× ×ס×
| ×ת×××× |
ת×ר×× ××××× |
ת××× ×§××× × |
Class Effect |
××¦× ×××× |
×ס×ס ×××××ת
|
| ×××× ×תרפ×× ×××פ×× ×סר×× ×תק×× ×ק××× ×× ×ר××¨×ª× ×©× ×ר×× ××©×ª× ××××× ××¢×× × ×¢× ××× ××××: ×. ××××ª× ×תק××× ×××ר שק××× ××פ×× ×××××ª×¨×¤× ×§××× ××ש×ר ש××× ×ª×¨×××ת פ×××× ×× ×××××ª× ××ר×רת×ת; ×. ××××ª× ×תק××× ×ת×× 12 ×××ש×× ×××פ×× ×××××ª×¨×¤× ××ש×ר ש××× ×ª×¨×××ת פ×××× ×× ××ס×רת ×ש×××× (adjuvant) ×× noeoadjuvant. ××××× ××××ª× ×××× ××××× ×××× ×תר××¤× ××ת ×××× ×תר×פ×ת ××שת××××ת ××שפ×ת ×-Checkpoint inhibitors. |
03/02/2022 |
××× ×§×××××× |
|
Urothelial carcinoma |
|
| ×××× ×תרפ×× ×××פ×× ×סר×× ×תק×× ×ק××× ×× ×ר××¨×ª× ×©× ×ר×× ××©×ª× ××××× ××¢×× × ×¢× ××× ××××: ×. ק××× ××פ×× ×××××ª×¨×¤× ×§××× ××ש×ר ש××× ×ª×¨×××ת פ×××× ×× ×××××ª× ××ר×רת×ת; ×. ××××ª× ×תק××× ×ת×× 12 ×××ש×× ×××פ×× ×××××ª×¨×¤× ××ש×ר ש××× ×ª×¨×××ת פ×××× ×× ××ס×רת ×ש×××× (adjuvant) ×× noeoadjuvant. ××××× ××××ª× ×××× ××××× ×××× ×תר××¤× ××ת ×××× ×תר×פ×ת ××שת××××ת ××שפ×ת ×-Checkpoint inhibitors. |
30/01/2020 |
××× ×§×××××× |
|
Urothelial carcinoma |
|
| ×תר××¤× ×ª×× ×ª× ×××פ×× ×סר×× ×××× ×תק×× ×× ×ר××¨×ª× ××§× ××פ×× ×¨×ש×× ×ש×××× ×¢× Axitinib ×××××× ××ר×ת ס×××× poor ×× intermediate. ××××× ××××ª× ×××× ××××× ×××× ×תר××¤× ××ת ×××× ×תר×פ×ת ××שת××××ת ××שפ×ת ×-Checkpoint inhibitors. |
30/01/2020 |
××× ×§×××××× |
|
RCC, Renal cell carcinoma |
|
| ×תר××¤× ×ª×× ×ª× ×××× ×תרפ×× ×××פ×× ×קרצ×× ××× ×ר×רת×ת ×ס×× Merkel cell. ××××× ××××ª× ×××× ××××× ×××× ×תר××¤× ××ת ×××× ×תר×פ×ת ××שת××××ת ××שפ×ת ×-Checkpoint inhibitors |
11/01/2018 |
××× ×§×××××× |
|
Merkel cell carcinoma |
|
| ×××× ×תרפ×× ×××פ×× ××××§× ×סר×× ×ר×× ×©×ª× ×תק×× ×ק××× ×× ×ר××¨×ª× ××××× ×©××××ª× ×× ×תק××× ××××× ××××תרפ×× ×××ססת פ×××× ×× ×©× ××ª× × ××§× ××פ×× ×¨×ש××, ××××× PDL1. ××××× ××××ª× ×××× ××××× ×××× ×תר××¤× ××ת ×××× ×תר×פ×ת ××שת××××ת ××שפ×ת ×-Checkpoint inhibitors. |
01/02/2023 |
××× ×§×××××× |
|
Urothlial cancer |
|
|
ש×××ש ×ס×
-
|
×ס×רת ××××× ×ס×
- ×. ×תר××¤× ×ª×× ×ª× ×××פ×× ××קר×× ××××:
- 1. ×××× ×תרפ×× ×××פ×× ×קרצ×× ××× ×ר×רת×ת ×ס×× Merkel cell.××××× ××××ª× ×××× ××××× ×××× ×תר××¤× ××ת ×××× ×תר×פ×ת ××שת××××ת ××שפ×ת ×-Checkpoint inhibitors2. ×××× ×תרפ×× ×××פ×× ×סר×× ×תק×× ×ק××× ×× ×ר××¨×ª× ×©× ×ר×× ××©×ª× ××××× ××¢×× × ×¢× ××× ××××:
- ×. ××××ª× ×תק××× ×××ר שק××× ××פ×× ×××××ª×¨×¤× ×§××× ××ש×ר ש××× ×ª×¨×××ת פ×××× ×× ×××××ª× ××ר×רת×ת;
- ×. ××××ª× ×תק××× ×ת×× 12 ×××ש×× ×××פ×× ×××××ª×¨×¤× ××ש×ר ש××× ×ª×¨×××ת פ×××× ×× ××ס×רת ×ש×××× (adjuvant) ×× noeoadjuvant. ××××× ××××ª× ×××× ××××× ×××× ×תר××¤× ××ת ×××× ×תר×פ×ת ××שת××××ת ××שפ×ת ×-Checkpoint inhibitors.×××× ×תרפ×× ×××פ×× ××××§× ×סר×× ×ר×× ×©×ª× ×תק×× ×ק××× ×× ×ר××¨×ª× ××××× ×©××××ª× ×× ×תק××× ××××× ××××תרפ×× ×××ססת פ×××× ×× ×©× ××ª× × ××§× ××פ×× ×¨×ש××, ××××× PDL1.
××××× ××××ª× ×××× ××××× ×××× ×תר××¤× ××ת ×××× ×תר×פ×ת ××שת××××ת ××שפ×ת ×-Checkpoint inhibitors.4.
×תר××¤× ×ª×× ×ª× ×××פ×× ×סר×× ×××× ×תק×× ×× ×ר××¨×ª× ××§× ××פ×× ×¨×ש×× ×ש×××× ×¢× Axitinib ×××××× ××ר×ת ס×××× poor ×× intermediate.
××××× ××××ª× ×××× ××××× ×××× ×תר××¤× ××ת ×××× ×תר×פ×ת ××שת××××ת ××שפ×ת ×-Checkpoint inhibitors.
- ×. ××ª× ×תר××¤× ×××××¨× ×××¢×©× ××¤× ××¨×©× ×©× ××××× ×××× ×§××××××.
|
|
| ×¢××× ×ר××¤× ××××ר×ת ××¢×××
|
Â
Â
|
| ××פ×ש ×××ר××
|
×××ר×× ×-PubMed
|
| ××××¢ ×רשת
|
RxList WebMD Drugs.com
|
| ×©× ×צר×
|
MERCK SERONO S.A., SWITZERLAND
|
| ×©× ××¢× ×ר×ש××
|
MERCK SERONO LTD
|
| ר×ש×××
|
ת×ר×× ××ש×: 6/2017. ר×ש××× ×ת×ר××:
|
| ת×ר×× ×¢×××× ××ר××
|
08/05/2024
|
ת××× ×ª ×ר×××
ת×ר×× ×¢××××: 08/05/2024
MERCK
××××× ×¦×× - Bavencio
true
השינוי האחרון נעשה בֹ־8 במאי 2024 ב־14:55
